Discover the interview of Ziad Julier, co-founder of start-up Orio Therapeutics, based at the BioArk in Monthey, on Radio Chablais. Ziad presents their new cardio-protective drug technology, currently in the development phase, and his entrepreneurial journey. > Listen here “Our ultimate goal is for an acute patient who has had a heart attack to be […]
Orio Therapeutics on Radio Chablais Read More »
Nanobactérie, whose AlphaOnco subsidiary is based at the BioArk in Monthey, announces a strategic partnership with EP Equity Investment (EPEI), a Luxembourg-based investment company.
Anti-cancer treatment: new high-profile investor for Nanobacteria! Read More »
ten23 health (based in Basel and at BioArk Visp) and Ypsomed announced that they are entering into a strategic partnership to advance thecommercialization of the YpsoDose wearable injector for subcutaneous self-injection of large-volume doses.
ten23 health collaborates with Ypsomed to market a new patch injector Read More »
A delegation of around fifty international life sciences specialists visited BioArk in Monthey on 24 April. It was an opportunity to get to know the Valais ecosystem in this field, with presentations by Valais start-ups and a conference by the Idiap research institute on artificial intelligence. The visit to the Valais was organised as part of Swiss Biotech Day, one of the biggest life sciences events in Switzerland.
An international delegation discovers BioArk in Monthey Read More »
Biotechgate Digital Partnering is an online event that runs four times a year to support the business development & licensing of Pharma, Biotech, Medtech and Digital Health companies. Biotechgate Digital Partnering usually hosts over 1,000 representatives from leading life science companies and investors from around the globe, including big pharma, biotech start-ups and corporate investors.
The next edition of the popular five-day international conference series will be held virtually from May 13 to 17, 2024, and is free to attend.
BioArk invites you to take part in the online event Biotechgate Digital Partnering Read More »
The HES-SO Valais-Wallis School of Engineering is today unveiling a major change in the way it promotes its educational offerings and research and innovation skills in the life sciences sector.
Over the past few years, the Swiss biopharmaceutical and food industries have undergone a rapid shift towards life sciences. Driven by innovation, collaboration and a commitment to health, wellbeing and sustainability, a number of partner companies of the Swiss College of Engineering (HEI), such as Debiopharm and Lonza, have massively expanded these business areas to meet the needs of the economy.
The HES-SO Valais-Wallis strengthens its national positioning in Life Sciences Read More »
The Valais life sciences ecosystem is in the spotlight this year, as the BioArk Monthey technology site will be a major stop for the delegation on Wednesday April 24. International players will be welcomed on our Monthey-Site, on April 24th.The Global Village is a platform hosted by the Swiss Biotech Association, in partnership with other Swiss
BioArk welcomes a Global Village delegation April 2024 ! Read More »
In a recent article published in the Agefi, the year 2023 saw a rise in mergers and acquisitions in the biotech sector, despite a slowdown in IPOs. While 2024 promises to be an optimistic year, investors are urged to be cautious about the haste of start-ups to go public.
2024: a promising year for biotech Read More »
Meet IHMA at the 2024 ECCMID conference in Barcelona from April 27 to 30, 2024. Rendez-vous at the booth Stand E67 ! Based on the Monthey-site of BioArk, the company IHMA is specialized in infectious diseases & offer the most comprehensive offering of products and services for developing and marketing antimicrobial agents. From April 27
IHMA Exhibiting and Presenting at ECCMID 2024 Read More »
Orio Therapeutics, a biotechnology company at the forefront of protein engineering for regenerative medicine, today announced the successful closure of a CHF 500,000 pre-seed funding round. This investment, secured from angel investors, will propel the company’s ambitious goal of revolutionizing treatment approaches for patients suffering from debilitating conditions.
Sion Site
Rue de l’Industrie 23
CH-1950 Sion
Tél. +41 (0) 58 332 21 20
info@bioark.ch
Monthey Site
Rte de l’Ile-au-bois 1A
CH-1870 Monthey
Tél. +41 (0) 58 332 21 20
info@bioark.ch
Massimo Nobile
| BioArk | Intranet BioArk Monthey
